Cat. No. 2190
Alternative Name: Lintitript
Chemical Name: 2-[[[4-(2-Chlorophenyl)-2-thiazolyl]amino]carbonyl]-1H-indole-1-acetic acid
Biological ActivityPotent, non-peptide CCK1 receptor antagonist that displays > 33-fold selectivity over CCK2 receptors (EC50 values are 6 and 200 nM respectively). Causes an increase in plasma leptin levels and increases food intake in rats in vivo.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Gully et al (1993) Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors. Eur.J.Pharmacol. 23 232.
Gouldson et al (1999) Contrasting roles of Leu356 in the human CCK1 receptor for antagonist SR 27897 and agonist SR 146131 binding. Eur.J.Pharmacol. 383 339. PMID: 10594328.
Cano et al (2003) Regulation of leptin distribution between plasma and cerebrospinal fluid by cholecystokinin receptors. Br.J.Pharmacol. 140 647. PMID: 14534148.
If you know of a relevant citation for this product please let us know.
Keywords: SR 27897, supplier, Potent, selective, CCK1, antagonists, Cholecystokinin1, Receptors, CCK, Cholecystokinin, SR27897
Find multiple products by catalog number
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.